HK Stock Market Move | JINHAI MED TECH (02225) rose more than 3% in the morning session, the company reached a cooperation agreement with Ningbo David Medical Device to jointly expand the global endoscope market.

JINHAI MED TECH (02225) rose more than 3% in early trading, up 3.4% as of press time to 1.52 Hong Kong dollars, with a turnover of 3,520,800 Hong Kong dollars. On the news front, JINHAI MED TECH announced that on July 2, 2025, its wholly-owned subsidiary Shanghai JINHAI MED TECH Co., Ltd. signed a five-year cooperation framework agreement with Ningbo David Medical Device Co., Ltd., a wholly-owned subsidiary of Ningbo David Medical Device Equipment Co., Ltd.(300314.SZ). Under the agreement, Shanghai JINHAI and Ningbo David Medical Device Group will collaborate on endoscope products in the international market, aiming to create competitive high-end medical device solutions. Endoscope products will form the basis of the long-term relationship between the two parties. It is expected that when the cooperation progresses, Verkaide Medical will have exclusive priority and exclusive overseas distribution rights for the group's rigid endoscope products. Shanghai JINHAI and Ningbo David Medical Device Group will leverage their respective comparative advantages in endoscope product production and sales to actively explore overseas markets, enhance product delivery efficiency and cost competitiveness through optimized resource allocation, supply chain coordination, and capacity linkage. Shanghai JINHAI will also cooperate with Verkaide Medical to promote the registration and international certification of endoscope products in various countries, accelerate the internationalization process of endoscope products, conduct clinical research at multiple research centers, establish an international academic exchange platform, and enhance the global academic influence of endoscope products through medical education, technical training, joint brand promotion, and other methods.